Lundbeck to Present a Breadth of Migraine and Cluster Headache Data at the 66th Annual Scientific Meeting of the American Headache Society

Lundbeck, a biopharmaceutical company based in Bothell, Washington, recently shared its positive findings on VYEPTI, their new prescription medicine for treating migraines in adults. New data shows that VYEPTI achieved prolonged reductions in headache frequency and severity, resulting in numerous patients achieving fewer than four headache days per month.

Study results also revealed that patients on VYEPTI self-reported a doubling of “good days” per month, with 86 percent of patients reporting improvements in brain fog after treatment. This achievement is particularly significant because a post-hoc analysis of the Phase 3 PROMISE-2 study revealed that interictal periods between headaches are associated with positive effects.

READ THE STORY at BioSpace »